Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities.


Journal

The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355

Informations de publication

Date de publication:
08 2019
Historique:
received: 07 11 2018
revised: 14 03 2019
accepted: 04 04 2019
pubmed: 17 7 2019
medline: 9 6 2020
entrez: 17 7 2019
Statut: ppublish

Résumé

Antiretroviral agents with long-acting properties have potential to improve treatment outcomes substantially for people living with HIV. In November 2017, the Long acting/Extended Release Antiretroviral Resource Program (LEAP) convened a workshop with the aim of shaping the research agenda and promoting early development of long-acting or extended release products for key populations: pregnant and lactating women, children aged up to 10 years, and adolescents aged 10-19 years. Goals included strategies and principles to ensure that the needs of children, adolescents, and pregnant and lactating women are considered when developing long-acting formulations. Research should focus not only on how best to transition long-acting products to these populations, but also on early engagement across sectors and among stakeholders. A parallel rather than sequential approach is needed when establishing adult, adolescent, and paediatric clinical trials and seeking regulatory approval. Pregnant and lactating women should be included in adult clinical trials. Adolescent-friendly trial design is needed to improve recruitment and retention of young people.

Identifiants

pubmed: 31307946
pii: S2352-3018(19)30147-X
doi: 10.1016/S2352-3018(19)30147-X
pmc: PMC7152795
pii:
doi:

Substances chimiques

Anti-Retroviral Agents 0
Delayed-Action Preparations 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e552-e558

Subventions

Organisme : NICHD NIH HHS
ID : HHSN275201800001C
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275201800001I
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI118397
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106716
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Curr Opin HIV AIDS. 2017 Jul;12(4):343-350
pubmed: 28368868
AIDS. 2014 Aug 24;28(13):1945-56
pubmed: 24845154
N Engl J Med. 2012 May 24;366(21):1998-2007
pubmed: 22621627
Trials. 2018 Jan 29;19(1):78
pubmed: 29378652
Curr Opin HIV AIDS. 2018 Jul;13(4):374-380
pubmed: 29794816
N Engl J Med. 2018 Sep 6;379(10):979-981
pubmed: 30037297
AIDS. 2011 Sep 24;25(15):1887-95
pubmed: 21785321
Clin Infect Dis. 2017 Jun 1;64(11):1597-1603
pubmed: 29190337
J Acquir Immune Defic Syndr. 2014 Jan 1;65 Suppl 1:S24-8
pubmed: 24321980
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):408-17
pubmed: 18614923
PLoS Med. 2016 Nov 1;13(11):e1002160
pubmed: 27802281
J Int AIDS Soc. 2015 Dec 02;18(Suppl 6):20270
pubmed: 26639117
J Paediatr Child Health. 2017 Jul;53(7):667-674
pubmed: 28383200
J Infect Dis. 2018 Jun 5;218(1):16-25
pubmed: 29514254
Int J Fem Approaches Bioeth. 2008 Fall;1(2):5-22
pubmed: 19774226
PLoS Med. 2018 Mar 30;15(3):e1002547
pubmed: 29601570
Obstet Gynecol. 2013 Nov;122(5):1077-81
pubmed: 24104789
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
AIDS Patient Care STDS. 2014 Mar;28(3):128-35
pubmed: 24601734
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):181-8
pubmed: 26361171
HIV Clin Trials. 2016 Nov;17(6):233-241
pubmed: 27801628
AIDS Patient Care STDS. 2009 Mar;23(3):185-94
pubmed: 19866536
Glob Health Sci Pract. 2017 Jun 27;5(2):182-187
pubmed: 28655797
J Acquir Immune Defic Syndr. 2010 Jul;54 Suppl 1:S18-24
pubmed: 20571419
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):477-80
pubmed: 25559590
PLoS One. 2013 Sep 10;8(9):e73556
pubmed: 24039981
Nat Commun. 2018 Jan 9;9(1):2
pubmed: 29317618
Curr Opin HIV AIDS. 2016 Jan;11(1):122-8
pubmed: 26633643
Curr Opin HIV AIDS. 2015 Jul;10(4):246-52
pubmed: 26049949
AIDS Care. 2008 Sep;20(8):958-68
pubmed: 18608073

Auteurs

Sharon Nachman (S)

Health Sciences Center, SUNY Stony Brook, Pediatrics, New York, NY, USA. Electronic address: sharon.nachman@stonybrook.edu.

Claire L Townsend (CL)

Johns Hopkins University, Baltimore, MD, USA.

Elaine J Abrams (EJ)

ICAP at Columbia, Mailman School of Public Health, Columbia University, New York, NY, USA; Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.

Moherndren Archary (M)

University of Kwa Zulu Natal, Durban, South Africa.

Edmund Capparelli (E)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, USA.

Polly Clayden (P)

HIV i-Base, London, UK.

Shahin Lockman (S)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.

Patrick Jean-Philippe (P)

Maternal Adolescent Pediatric Research Branch, DAIDS/NIAID/NIH, Rockville, MD, USA.

Kenneth Mayer (K)

School of Medicine, Harvard University, Cambridge, MA, USA.

Mark Mirochnick (M)

Boston University School of Medicine, Boston, MA, USA.

Jane McKenzie-White (J)

Johns Hopkins University, Baltimore, MD, USA.

Kimberly Struble (K)

Food and Drug Administration, Silver Spring, MD, USA.

Heather Watts (H)

Office of the Global AIDS Coordinator and Health Diplomacy, Washington, DC, USA.

Charles Flexner (C)

Johns Hopkins University, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH